Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
troxacitabine · 1 trial · 1 indication
Conventional Response Rate defined as the achievement of complete hematologic remission (CHR), partial hematologic remission (PHR), hematologic improvement (HI), partial response (PR), or back to chronic phase (BCP).
| Arm | Type | Description |
|---|---|---|
| troxacitabine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| troxacitabine | DRUG | - |
DISEASE CHARACTERISTICS: Diagnosis of Philadelphia chromosome-positive blastic phase chronic myelogenous leukemia (CML) with blasts of non-lymphoid origin Blastic phase defined as: At least 30% blasts in the blood or bone marrow OR Presence of extramedullary infiltration outside the liver or spleen ...
Top 20 of 60 competitors
Troxacitabine is an investigational small molecule being studied for the treatment of leukemia, specifically chronic myelogenous leukemia. It has been evaluated in a Phase 2 clinical trial in patients with this condition. It is not an approved therapy and remains in clinical development.
Troxacitabine targets DNA polymerases, including POLA1, POLD1, POLD2, POLD3, POLD4, and POLE. It acts as an inhibitor of these enzymes. By inhibiting DNA polymerases, troxacitabine interferes with DNA synthesis and replication in cancer cells.
Troxacitabine is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is responsible for its clinical development in leukemia.
Troxacitabine is in Phase 2 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 2 trial evaluating it in chronic myelogenous leukemia has been completed.
Troxacitabine has been studied in one completed Phase 2 trial, NCT00012259, titled "Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia." The trial enrolled 31 patients in the United States and Canada. It was an uncontrolled, non-randomized study.